Continuum Advisory, LLC Amgen Inc Transaction History

Continuum Advisory, LLC

$680 Million
Q2 2024

A detailed history of Continuum Advisory, LLC transactions in Amgen Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 4,499 shares of AMGN stock, worth $1.45 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

4,499

Previous 4,486 0.29%

Holding current value

$1.45 Million

Previous $1.28 Million 10.2%

% of portfolio

0.21%

Previous 0.19%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$262.75 - $319.31 $3,415 - $4,151	13 Added 0.29%	4,499 $1.41 Million
Q1 2024 May 10, 2024	SELL	$268.87 - $324.56 $224,775 - $271,332	-836 Reduced 15.71%	4,486 $1.28 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $252,375 - $284,710	987 Added 22.77%	5,322 $1.53 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $292,991 - $363,756	1,340 Added 44.74%	4,335 $1.17 Million
Q2 2023 Dec 13, 2023	SELL	$214.27 - $253.37 $24,426 - $28,884	-114 Reduced 3.67%	2,995 $664,000
Q2 2023 Aug 10, 2023	SELL	$214.27 - $253.37 $24,426 - $28,884	-114 Reduced 3.67%	2,995 $664,000
Q1 2023 Dec 13, 2023	BUY	$225.79 - $275.2 $22,804 - $27,795	101 Added 3.36%	3,109 $751,000
Q1 2023 May 12, 2023	BUY	$225.79 - $275.2 $22,804 - $27,795	101 Added 3.36%	3,109 $751,000
Q4 2022 Dec 13, 2023	BUY	$229.03 - $291.01 $57,944 - $73,625	253 Added 9.18%	3,008 $790,000
Q4 2022 Feb 10, 2023	BUY	$229.03 - $291.01 $57,944 - $73,625	253 Added 9.18%	3,008 $790,000
Q3 2022 Dec 13, 2023	SELL	$224.46 - $253.15 $9,427 - $10,632	-42 Reduced 1.5%	2,755 $620,000
Q3 2022 Nov 08, 2022	SELL	$224.46 - $253.15 $9,427 - $10,632	-42 Reduced 1.5%	2,755 $621,000
Q2 2022 Dec 13, 2023	BUY	$230.71 - $256.74 $47,295 - $52,631	205 Added 7.91%	2,797 $680,000
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $47,295 - $52,631	205 Added 7.91%	2,797 $681,000
Q1 2022 Dec 13, 2023	BUY	$219.27 - $242.57 $200,193 - $221,466	913 Added 54.38%	2,592 $626,000
Q1 2022 May 17, 2022	BUY	$219.27 - $242.57 $200,193 - $221,466	913 Added 54.38%	2,592 $604,000
Q4 2021 Dec 13, 2023	SELL	$198.88 - $227.6 $117,538 - $134,511	-591 Reduced 26.04%	1,679 $377,000
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $117,538 - $134,511	-591 Reduced 26.04%	1,679 $378,000
Q3 2021 Dec 13, 2023	BUY	$212.27 - $248.7 $90,639 - $106,194	427 Added 23.17%	2,270 $482,000
Q3 2021 Nov 08, 2021	BUY	$212.27 - $248.7 $90,639 - $106,194	427 Added 23.17%	2,270 $483,000
Q2 2021 Dec 13, 2023	SELL	$233.58 - $259.14 $582,081 - $645,776	-2,492 Reduced 57.49%	1,843 $449,000
Q2 2021 Aug 17, 2021	BUY	$233.58 - $259.14 $430,487 - $477,595	1,843 New	1,843 $449,000
Q3 2020 May 17, 2021	SELL	$234.65 - $260.95 $201,095 - $223,634	-857 Closed	0 $0
Q2 2020 May 18, 2021	BUY	$197.81 - $242.74 $169,523 - $208,028	857 New	857 $219,000
Q1 2019 May 18, 2021	SELL	$180.87 - $203.88 $252,132 - $284,208	-1,394 Closed	0 $0
Q4 2018 May 18, 2021	SELL	$178.4 - $208.25 $40,496 - $47,272	-227 Reduced 14.0%	1,394 $271,000
Q3 2018 May 18, 2021	SELL	$185.29 - $208.89 $166,205 - $187,374	-897 Reduced 35.62%	1,621 $335,000
Q2 2018 May 18, 2021	SELL	$166.05 - $186.51 $13,284 - $14,920	-80 Reduced 3.08%	2,518 $465,000
Q1 2018 May 18, 2021	SELL	$169.43 - $198.0 $234,999 - $274,626	-1,387 Reduced 34.81%	2,598 $443,000
Q4 2017 May 18, 2021	BUY	$168.79 - $188.59 $18,735 - $20,933	111 Added 2.87%	3,985 $693,000
Q3 2017 May 18, 2021	SELL	$167.29 - $191.0 $11,041 - $12,606	-66 Reduced 1.68%	3,874 $722,000
Q2 2017 May 18, 2021	BUY	N/A	737 Added 23.01%	3,940 $679,000
Q1 2017 May 18, 2021	BUY	N/A	3,203	3,203 $526,000

Others Institutions Holding AMGN

# of Institutions

3,054

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $173B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.

Account

Continuum Advisory, LLC Amgen Inc Transaction History